NanoViricides, Inc. (NYSE American: NNVC) announced it has applied to the Democratic Republic of Congo's regulatory agency for approval to initiate a Phase II clinical trial evaluating its NV-387 Oral Gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company has retained Om Sai Clinical Research Private Limited as the contract research organization for the study, with drug supplies already positioned in the DRC. NV-387 is an orally administered broad-spectrum antiviral designed to target host-side mechanisms that viruses rely on to infect cells, which may reduce the likelihood of viral resistance.
The planned study builds on NanoViricides' ongoing Phase II Mpox trial in the DRC and comes as the company seeks to address an outbreak that, according to the release, has resulted in more than 930 deaths and nearly 2,400 confirmed cases since May. The company believes NV-387's oral formulation could offer logistical advantages over infusion-based therapies in resource-limited settings. If successful, the drug could support development of a broad-spectrum treatment for Ebola and other filoviruses.
The full press release is available at https://ibn.fm/tmrCX. NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy, with its lead drug candidate NV-387 also being developed for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections. The company's platform technology is based on the TheraCour nanomedicine technology, licensed from TheraCour Pharma, Inc.
This trial represents a critical step in addressing an ongoing health crisis in the DRC, where the ebolavirus outbreak has claimed hundreds of lives. The oral formulation of NV-387 could simplify administration in remote areas where intravenous treatments are challenging to deliver. The company's approach of targeting host mechanisms may also provide a therapeutic option less prone to viral resistance, a significant concern in treating RNA viruses like Ebola.
For more information on NanoViricides and its pipeline, visit the company's newsroom at https://ibn.fm/NNVC.
